Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDT | P30046 | 1/20 | 1.00 |
| ▸ | AXL | P30530 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.49 |
| ▸ | KMO | O15229 | 2/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.48 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.45 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | BLVRB | P30043 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | KDM6B | O15054 | 1/20 | 0.45 |
| ▸ | TET3 | O43151 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.45 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM5C | P41229 | 1/20 | 0.45 |
| ▸ | ASPH | Q12797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2806999 | 1.00 | DDT (1.00) | DDTAXLFOLH1KMOPLA2G2A | |
| SCHEMBL686861 | 0.85 | DDT (0.74) | DDTKMOKDM4EALDH1A1ASPH | |
| SCHEMBL29914342 | 0.85 | DDT (0.74) | DDTKMOKDM4EALDH1A1ASPH | |
| SCHEMBL10782352 | 0.80 | DDT (0.67) | DDTFOLH1KMOPLA2G2APTPN11 | |
| SCHEMBL28557056 | 0.78 | DDT (0.62) | DDTKDM4EKDM6BTET3KDM4A | |
| SCHEMBL2947834 | 0.77 | KMO (0.63) | DDTFOLH1KMOPLA2G2APTPN11 | |
| SCHEMBL29400093 | 0.77 | KMO (0.63) | DDTFOLH1KMOPLA2G2APTPN11 | |
| SCHEMBL31733899 | 0.77 | DDT (0.62) | DDTAXLFOLH1KMOALDH1A1 | |
| SCHEMBL29772925 | 0.76 | DDT (0.61) | DDTAXLKMOMAP4K4RXRA | |
| SCHEMBL28563936 | 0.76 | DDT (0.61) | DDTAXLKMOMAP4K4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117185996-B | Intermediate of 4-CPPC and preparation method thereof | 烟台皓元生物医药科技有限公司 | 2026-03-20 | — | — | CN | disclosed |
| CN-117185996-B | Intermediate of 4-CPPC and preparation method thereof | 烟台皓元生物医药科技有限公司 | 2026-03-20 | — | — | CN | disclosed |
| CN-118028474-B | Use of substance for removing nucleated red blood cells in spleen of patient in preparation of medicine for treating acute myelogenous leukemia | 细胞生态海河实验室 | 2024-07-09 | — | — | CN | disclosed |
| CN-118028474-A | Use of substance for removing nucleated red blood cells in spleen of patient in preparation of medicine for treating acute myelogenous leukemia | 细胞生态海河实验室 | 2024-05-14 | — | — | CN | disclosed |
| US-20240139241-A1 | COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY | CREATE MEDICINES, INC. | 2024-05-02 | — | — | US | disclosed |
| EP-4326286-A2 | COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY | Myeloid Therapeutics, Inc. (US) | 2024-02-28 | — | — | EP | disclosed |
| WO-2024039683-A1 | COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY | MYELOID THERAPEUTICS, INC. (US) | 2024-02-22 | — | — | WO | disclosed |
| CN-117185996-A | Intermediate of 4-CPPC and preparation method thereof | 烟台皓元生物医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117185996-A | Intermediate of 4-CPPC and preparation method thereof | 烟台皓元生物医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| CN-117185996-A | Intermediate of 4-CPPC and preparation method thereof | 烟台皓元生物医药科技有限公司 | 2023-12-08 | — | — | CN | disclosed |
| WO-2023031246-A1 | SUBSTITUTED THIOPHENE COMPOUNDS AS D-DOPACHROME TAUTOMERASE INHIBITORS | RIJKSUNIVERSITEIT GRONINGEN (NL) | 2023-03-09 | — | — | WO | disclosed |
| WO-2022226355-A2 | COMPOSITIONS AND METHODS FOR CONDITIONING PATIENTS FOR CELL THERAPY | MYELOID THERAPEUTICS, INC. (US) | 2022-10-27 | — | — | WO | disclosed |